Regenerative Medicine Market Size Worth USD 40.6 billion by 2027

Regenerative Medicine Market is projected to reach USD 40.6 billion by 2027 from USD 12.2 billion in 2022, at a CAGR of 27.2% according to a new report by MarketsandMarkets™. The major factors driving the growth of the regenerative medicine market are the availability of funding and rising investments in R&D, increasing clinical trials for stem cells and CAR-T cell therapies, and rising advancements in tissue engineered products.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Browse in-depth TOC on "Regenerative Medicine Industry"
193 - Tables
49 - Figures
192 - Pages

Cell therapy segment accounted for the largest share of the regenerative medicine market

Based on the product, the regenerative medicine market is segmented into musculoskeletal disorders, oncology, dermatology & wound care, ophthalmology, cardiovascular diseases, and other applications. In 2021, the musculoskeletal disorders segment accounted for the largest share of the global regenerative medicine market. Growth in this market segment can be attributed to the rising research on musculoskeletal regeneration and prevalence of orthopedic disorders.

Musculoskeletal disorder is the largest-growing application segment of the regenerative medicine industry
Based on application, the regenerative medicine market is segmented into academic & research institutes, contract research organizations (CROs), and pharmaceutical & biotechnology companies. In 2021, the academic & research institutes segment accounted for the largest share of the regenerative medicine market. Market growth can largely be attributed to the increase in research intensity in this end-user segment and the availability of sufficient grants and funds for research.

Request Free Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

North America accounted for the largest share of the stem cell therapy industry

North America held the largest share in the global market, followed by Europe. The large share of the North American regional segment can be attributed to the increase in research targeted toward developing cell-based therapies in the past decade and increasing research activities in regenerative medicine and growing awareness of personalized medicine have also resulted in the establishment of stem cell banking and tissue engineering.

Gene Therapy Industry Dynamics:

Drivers:
• Rising prevalence of chronic diseases, genetic disorders, and cancer
• Rising investments in regenerative medicine research
• Growing pipeline of regenerative medicine products

Restraints:
• Ethical concerns related to the use of embryonic stem cells in research & development
• High cost of cell and gene therapies

Opportunities:
• Implementation of the 21st Century Cures Act
• Rising demand for organ transplantations

Key Market Players:

The regenerative medicine market is consolidated in nature with prominent players in the regenerative medicine market include Novartis AG (Switzerland), Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Smith & Nephew plc (UK), Medipost Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd (Japan), Takeda Pharmaceutical Company (Japan), CORESTEM, Inc (South Korea), Vericel Corporation (US), MIMEDX (US), Organogenesis Inc. (US), Medtronic plc (US), Orthocell Ltd. (Australia), Mesoblast Ltd (Australia), BioRestorative Therapies, Inc (US), Pluri Inc. (Israel), Tegoscience (South Korea), Anterogen Co., Ltd. (South Korea), bluebird bio, Inc. (US), APAC Biotech (India), Shenzhen SiBiono Genetech Co., Ltd. (China), Aspect Biosystems (Canada), and Athersys, Inc. (US)

Recent Developments:

• In 2022, Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function.

• In 2020, AbbVie acquired Allergan to enhance its product portfolio in immunology, hematologic oncology, neuroscience, and Allergan aesthetics.

• In 2022, MiMedx announced the launch of Axiofill, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue. Axiofill is a human placental-derived particulate product available for surgical recovery procedures.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65442579&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

This release was published on openPR.